View PDF Version - RePub - Erasmus Universiteit Rotterdam
View PDF Version - RePub - Erasmus Universiteit Rotterdam
View PDF Version - RePub - Erasmus Universiteit Rotterdam
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Chapter 4.3<br />
224<br />
References<br />
1. Kane M. Global programme for control of hepatitis B infection. Vaccine 1995;13 Suppl 1:S47-9.<br />
2. Lok AS, Lai CL, Leung N, Yao GB, Cui ZY, Schiff ER, Dienstag JL, Heathcote EJ, Little NR,<br />
Griffi ths DA, Gardner SD, Castiglia M. Long-term safety of lamivudine treatment in patients<br />
with chronic hepatitis B. Gastroenterology 2003;125:1714-22.<br />
3. Fung SK, Chae HB, Fontana RJ, Conjeevaram H, Marrero J, Oberhelman K, Hussain M, Lok<br />
AS. Virologic response and resistance to adefovir in patients with chronic hepatitis B. J<br />
Hepatol 2006;44:283-90.<br />
4. Sherman M, Yurdaydin C, Sollano J, Silva M, Liaw YF, Cianciara J, Boron-Kaczmarska A,<br />
Martin P, Goodman Z, Colonno R, Cross A, Denisky G, Kreter B, Hindes R. Entecavir for<br />
treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology<br />
2006;130:2039-49.<br />
5. Cooksley WG, Piratvisuth T, Lee SD, Mahachai V, Chao YC, Tanwandee T, Chutaputti A,<br />
Chang WY, Zahm FE, Pluck N. Peginterferon alpha-2a (40 kDa): an advance in the treatment<br />
of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat 2003;10:298-305.<br />
6. Janssen HL, van Zonneveld M, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, Simon C, So<br />
TM, Gerken G, de Man RA, Niesters HG, Zondervan P, Hansen B, Schalm SW. Pegylated<br />
interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic<br />
hepatitis B: a randomised trial. Lancet 2005;365:123-9.<br />
7. Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, Gane E, Fried MW,<br />
Chow WC, Paik SW, Chang WY, Berg T, Flisiak R, McCloud P, Pluck N. Peginterferon Alfa-2a,<br />
lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med<br />
2005;352:2682-95.<br />
8. Marcellin P, Lau GK, Bonino F, Farci P, Hadziyannis S, Jin R, Lu ZM, Piratvisuth T, Germanidis<br />
G, Yurdaydin C, Diago M, Gurel S, Lai MY, Button P, Pluck N. Peginterferon alfa-2a alone,<br />
lamivudine alone, and the two in combination in patients with HBeAg-negative chronic<br />
hepatitis B. N Engl J Med 2004;351:1206-17.<br />
9. Chan HL, Leung NW, Hui AY, Wong VW, Liew CT, Chim AM, Chan FK, Hung LC, Lee YT, Tam<br />
JS, Lam CW, Sung JJ. A randomized, controlled trial of combination therapy for chronic<br />
hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine<br />
alone. Ann Intern Med 2005;142:240-50.<br />
10. ter Borg MJ, van Zonneveld M, Zeuzem S, Senturk H, Akarca US, Simon C, Hansen BE,<br />
Haagmans BL, de Man RA, Schalm SW, Janssen HL. Patterns of viral decline during PEGinterferon<br />
alpha-2b therapy in HBeAg-positive chronic hepatitis B: Relation to treatment<br />
response. Hepatology 2006;44:721-727.<br />
11. Neumann AU. Hepatitis B viral kinetics: a dynamic puzzle still to be resolved. Hepatology<br />
2005;42:249-54.